However, the expression of these PD-Ls was higher in CD14+ cells obtained from the same patients at advanced HCC stages (PD-L1: 50.0 ± 7.8%, PD-L2: 36.2 ± 3.9%). Here, CD14 is linked to hepatocellular carcinoma.